Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of K-877 (Pemafibrate) in Chinese Patients With High TG and Low HDL-C
NCT04998981Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pemafibrate in hypertriglyceridemia and hypoalphalipoproteinemia (4 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Percent change in fasting TG versus placebo at 12 weeks and Percent change in fasting TG versus fenofibrate at 12 weeks. Started Sep 2021; status: completed.
02
Drugs
pemafibrate
03
Conditions
hypertriglyceridemiahypoalphalipoproteinemia
Beyond the preview
Go deeper on NCT04998981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998981.